MK0859

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Ambulatory Blood Pressure

Conditions

Ambulatory Blood Pressure

Trial Timeline

Jul 1, 2006 → Sep 1, 2006

NCT ID

NCT00565006

About MK0859

MK0859 is a phase 1 stage product being developed by Merck for Ambulatory Blood Pressure. The current trial status is completed. This product is registered under clinical trial identifier NCT00565006. Target conditions include Ambulatory Blood Pressure.

What happened to similar drugs?

1 of 1 similar drugs in Ambulatory Blood Pressure were approved

Approved (1) Terminated (0) Active (0)

✅ertapenemMerckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00565006	Phase 1	Completed	Jul 1, 2006	Sep 1, 2006	Ambulatory Blood Pressure
NCT00565292	Phase 1	Completed	Jul 1, 2006	Aug 1, 2006	Hypercholesterolemia
NCT00325455	Phase 2	Terminated	Jun 1, 2006	Mar 1, 2007	Hypercholesterolemia

Competing Products

1 competing product in Ambulatory Blood Pressure

See all competitors

Product	Company	Stage	Hype Score
ertapenem	Merck	Approved	43